- Home
- SRPT vs WGS Comparison
SRPT vs WGS Comparison
Compare SRPT & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRPT | WGS |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRPT | WGS |
|---|---|---|
| Price | $21.00 | $164.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 28 | 8 |
| Target Price | $26.00 | ★ $130.63 |
| AVG Volume (30 Days) | ★ 6.1M | 514.5K |
| Earning Date | 11-03-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $2,413,715,000.00 | $402,190,000.00 |
| Revenue This Year | $10.20 | $39.54 |
| Revenue Next Year | N/A | $22.50 |
| P/E Ratio | ★ N/A | $2,316.67 |
| Revenue Growth | 47.15 | ★ 50.50 |
| 52 Week Low | $10.42 | $55.17 |
| 52 Week High | $138.81 | $170.75 |
Technical Indicators
Market Signals| Indicator | SRPT | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 73.47 |
| Support Level | $15.94 | $119.43 |
| Resistance Level | $21.21 | $170.75 |
| Average True Range (ATR) | 1.26 | 9.18 |
| MACD | 0.42 | 3.28 |
| Stochastic Oscillator | 96.02 | 90.10 |
Price Performance
Historical ComparisonAbout SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.